Avacta Group plc
("Avacta" or the "Group" or the "Company")
Appointment of Zeus Capital as Joint Broker to Avacta Group plc
LONDON and PHILADELPHIA - June 30, 2025 - Avacta Therapeutics (AIM: AVCT), a life sciences company developing innovative, targeted oncology drugs, today announces
the appointment of Zeus Capital as a joint broker to the Company with immediate effect.
Peel Hunt and Panmure Liberum both continue in their respective roles as NOMAD and Joint Broker and Joint Broker to the Company.
Related Party Transaction
Richard Hughes, a Director of the Company, is an associate of Zeus Capital as defined under the AIM Rules. Zeus Capital is therefore a related party of the Company pursuant to the AIM Rules and the appointment of Zeus Capital including a £75,000 annual retainer due to Zeus Capital is a related party transaction. The Directors (other than Richard Hughes who is an associate of Zeus Capital) consider, having consulted with the Company's nominated adviser Peel Hunt, that the appointment of Zeus Capital including the annual retainer are fair and reasonable insofar as Shareholders are concerned.
-Ends-
For further information from Avacta Group plc, please contact:
Avacta Group plc Michael Vinegrad, Group Communications Director | |
Peel Hunt (Nomad and Joint Broker) James Steel / Chris Golden | |
Panmure Liberum (Joint Broker) Emma Earl / Will Goode / Mark Rogers Zeus (Joint Broker) James Hornigold / George Duxberry Dominic King ICR Healthcare Mary-Jane Elliott / Jessica Hodgson / Stephanie Cuthbert | https://panmureliberum.com/ |
Investor Contact Renee Leck THRUST Strategic Communications | |
Media Contact Carly Scaduto Carly Scaduto Consulting |
About Avacta - www.avacta.com
Avacta Therapeutics is a clinical-stage life sciences company expanding the reach of highly potent cancer therapies with the pre|CISION® platform. pre|CISION® is a proprietary warhead delivery system based on a tumor-specific protease (fibroblast activation protein or FAP) that is designed to concentrate highly potent warheads in the tumor microenvironment while sparing normal tissues. Our innovative pipeline consists of pre|CISION® peptide drug conjugates (PDC) or Affimer® drug conjugates (AffDC) that leverage the tumor-specific release mechanism, providing unique benefits over traditional antibody drug conjugates.